查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575048

颅内治疗递送市场，按治疗方法、适应症、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Intracranial Therapeutic Delivery Market, By Therapy, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年颅内治疗递送市场规模为198,032万美元，2024年至2032年复合年增长率为7.99%。

该领域的创新旨在透过精确靶向、持续释放和增强药物的生物利用度来改善患者的治疗结果。随着研究的进展，市场也看到了神经学应用的基因治疗和生物製剂的发展。神经系统疾病的日益普及和医疗技术的进步是推动该领域需求的关键因素，使其成为现代医疗保健的关键领域。

颅内治疗递送市场-市场动态

神经系统疾病盛行率的增加推动了对标靶治疗的需求。

神经系统疾病盛行率的增加是颅内治疗递送市场的重要驱动力。随着人口老化，阿兹海默症、帕金森氏症和多发性硬化症等疾病变得越来越常见，需要先进的治疗方案。据 CDC 称，预计 2020 年美国有六分之一的成年人患有神经系统疾病。

此外，提高意识和早期诊断有助于越来越多的患者寻求专门护理。随着医疗保健系统努力应对这些挑战，新型颅内输送方法的研发投资预计将扩大，为市场成长创造机会。

颅内治疗递送市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 7.99% 左右的复合年增长率成长

根据治疗细分，基因治疗预计将在 2023 年显示最大的市场份额

根据适应症细分，多发性硬化症是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

颅内治疗递送市场-細項分析：

全球颅内治疗递送市场根据治疗、适应症和区域进行细分。

根据疗法，市场分为三类：细胞疗法、基因疗法和酵素替代疗法。基因治疗是颅内治疗递送市场中最突出的。这种方法有可能解决神经系统疾病的潜在遗传原因，提供长期解决方案而不仅仅是缓解症状。载体技术和 CRISPR 基因编辑的进步正在增强基因疗法的功效和安全性，使其对于遗传性癫痫和神经退化性疾病等疾病越来越可行。对个人化医疗的日益关注进一步推动了对基因治疗的需求，因为治疗可以根据个别基因谱进行客製化。总体而言，其创新性和变革潜力使基因治疗成为市场的领先领域。

根据适应症，市场分为四类：脊髓性肌肉萎缩症（SMA）、多发性硬化症、巴顿氏症和肌肉萎缩侧索硬化症。多发性硬化症（MS）是颅内治疗递送市场中最突出的。多发性硬化症影响着全球数百万人，导致对能够控制其复杂症状并减缓疾病进展的创新治疗方案的巨大需求。包括单株抗体和口服治疗在内的疗法的进步正在改善患者的治疗效果并推动市场成长。多发性硬化症的盛行率不断上升，以及对更有效的给药方法的持续研究，强调了其作为治疗开发焦点的重要性。随着认识和诊断的提高，多发性硬化症相关治疗的市场不断扩大，巩固了其主导地位。

颅内治疗递送市场 - 地理洞察

北美成为颅内治疗递送市场最大的地区，主要得益于领先的医疗保健公司、先进的研究设施和强大的监管框架的存在。尤其是美国，由于医疗保健支出高、对创新的高度重视以及容易患神经系统疾病的人口老化，占据了很大的份额。此外，有利的报销政策和完善的临床试验基础设施支持市场成长。

该地区对神经学研究的投资也不断增加，这促进了新治疗方式的发展。虽然欧洲和亚太地区是需求不断增长的新兴市场，但北美成熟的医疗保健生态系统继续引领步伐，使其成为寻求颅内治疗交付创新的现有参与者和新进者的焦点。

颅内治疗递送市场-竞争格局：

颅内治疗递送市场的特征是老牌企业和新兴生技公司之间竞争激烈。美敦力（Medtronic）和艾伯维（AbbVie）等主要公司以其广泛的产品组合和强大的研发能力占据主导地位，专注于先进的药物输送系统和神经系统疾病的创新疗法。此外，史赛克和波士顿科学公司利用其在手术设备领域的强大影响力来提高治疗效果。

NeuroRx 和 Zynerba Pharmaceuticals 等新兴企业正在引入新颖的治疗方式，包括基于大麻素的疗法，这使市场格局多样化。随着公司寻求加速创新和扩大市场范围，协作和策略伙伴关係很常见。监管挑战和临床验证的需求仍然是影响竞争策略的关键障碍。总体而言，随着技术的进步和对神经系统疾病的更深入了解推动新产品开发，市场有望成长。

最新进展：

2024 年 9 月，CereVasc 的血管内装置有潜力成为直接向大脑进行基因治疗的新型输送系统，从而提高神经系统疾病的治疗效果。透过利用这种方法，旨在增强标靶治疗，同时最大限度地减少与传统方法相关的侵入性和副作用。

目录

第一章：颅内治疗递送市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 颅内治疗递送市场片段（依疗法）
    • 依适应症分類的颅内治疗递送市场片段
    • 按国家/地区分類的颅内治疗递送市场片段
    • 按地区分類的颅内治疗递送市场片段
  • 竞争洞察

第 3 章：颅内治疗递送主要市场趋势

  • 颅内治疗递送市场驱动因素
    • 市场驱动因素的影响分析
  • 颅内治疗递送市场的限制
    • 市场限制影响分析
  • 颅内治疗递送市场机会
  • 颅内治疗递送市场未来趋势

第 4 章：颅内治疗递送产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：颅内治疗递送市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：颅内治疗递送市场格局

  • 2023 年颅内治疗递送市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：颅内治疗递送市场 - 按治疗

  • 概述
    • 按疗法分類的细分市场份额分析
    • 细胞疗法
    • 基因治疗
    • 酵素替代疗法

第 8 章：颅内治疗递送市场 - 按适应症

  • 概述
    • 按指标分類的细分市场占有率分析
    • 脊髓性肌肉萎缩症 (SMA)
    • 多发性硬化症
    • 巴顿病
    • 肌萎缩侧索硬化症
    • 其他的

第 9 章：颅内治疗递送市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美颅内治疗传输主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗）
    • 北美市场规模和预测（按指标）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲颅内治疗传输主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按治疗）
    • 欧洲市场规模与预测（按指标）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区颅内治疗传递主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗）
    • 亚太地区市场规模与预测（依指标）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲颅内治疗传输主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按疗法）
    • 拉丁美洲市场规模与预测（按指标）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲颅内治疗传输主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模和预测（按治疗）
    • 中东和非洲市场规模及预测（依指标）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析 - 颅内治疗输送产业

  • 竞争仪表板
  • 公司简介
    • Medtronic
    • AbbVie
    • Stryker Corporation
    • Baxter International
    • Ipsen SA
    • Johnson & Johnson (Ethicon)
    • NuVasive
    • NeuroRx
    • CureVac AG
    • Boston Scientific
    • Aesculap
    • Zynerba Pharmaceuticals
    • Elekta
    • Intra-Cellular Therapies

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4050

REPORT HIGHLIGHT

Intracranial Therapeutic Delivery Market size was valued at USD 1,980.32 Million in 2023, expanding at a CAGR of 7.99% from 2024 to 2032.

The intracranial therapeutic delivery market focuses on methods and technologies used to administer treatments directly into the cranial cavity, targeting conditions such as brain tumors, epilepsy, and neurodegenerative disorders. This market encompasses a variety of delivery systems, including implantable devices, infusions, and drug-eluting technologies that optimize therapeutic efficacy and minimize side effects.

Innovations in this field aim to improve patient outcomes through precise targeting, sustained release, and enhanced bioavailability of medications. As research progresses, the market is also seeing developments in gene therapy and biologics for neurological applications. The growing prevalence of neurological disorders and advances in medical technology are key factors driving demand in this sector, making it a critical area of focus in modern healthcare.

Intracranial Therapeutic Delivery Market- Market Dynamics

Increased prevalence of neurological disorders driving demand for targeted therapies.

The increasing prevalence of neurological disorders is a significant driver for the intracranial therapeutic delivery market. As the population ages, conditions such as Alzheimer's, Parkinson's, and multiple sclerosis are becoming more common, necessitating advanced treatment options. According to the CDC, an estimated 1 in 6 adults in the U.S. reported having a neurological condition in 2020. This rising incidence fuels the demand for innovative therapeutic delivery systems that can provide targeted and effective treatments.

Furthermore, greater awareness and early diagnosis contribute to the growing patient pool seeking specialized care. As healthcare systems strive to address these challenges, investments in research and development for novel intracranial delivery methods are expected to expand, creating opportunities for market growth.

Intracranial Therapeutic Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.99% over the forecast period (2024-2032)

Based on Therapy segmentation, Gene Therapy, was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Multiple Sclerosis was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Intracranial Therapeutic Delivery Market- Segmentation Analysis:

The Global Intracranial Therapeutic Delivery Market is segmented based on Therapy, Indication, and Region.

The market is divided into three categories based on Therapy: Cell-based Therapy, Gene Therapy, and Enzyme Replacement Therapy. Gene Therapy is the most prominent in the intracranial therapeutic delivery market. This approach offers the potential to address the underlying genetic causes of neurological disorders, providing long-term solutions rather than just symptomatic relief. Advances in vector technology and CRISPR gene editing are enhancing the efficacy and safety of gene therapies, making them increasingly viable for conditions like genetic forms of epilepsy and neurodegenerative diseases. The growing focus on personalized medicine further propels the demand for gene therapy, as treatments can be tailored to individual genetic profiles. Overall, its innovative nature and transformative potential position gene therapy as a leading segment in the market.

The market is divided into four categories based on Indication: Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Batten Disease, and Amyotrophic Lateral Sclerosis. Multiple Sclerosis (MS) is the most prominent in the intracranial therapeutic delivery market. MS affects millions globally, leading to significant demand for innovative treatment options that can manage its complex symptoms and slow disease progression. Advances in therapies, including monoclonal antibodies and oral treatments, are enhancing patient outcomes and driving market growth. The increasing prevalence of MS, along with ongoing research into more effective delivery methods, underscores its importance as a focal point for therapeutic development. As awareness and diagnosis improve, the market for MS-related treatments continues to expand, solidifying its position as a dominant segment.

Intracranial Therapeutic Delivery Market- Geographical Insights

North America stands out as the largest region in the intracranial therapeutic delivery market, driven primarily by the presence of leading healthcare companies, advanced research facilities, and a robust regulatory framework. The United States, in particular, accounts for a significant share due to high healthcare expenditure, a strong emphasis on innovation, and an aging population prone to neurological disorders. Additionally, favorable reimbursement policies and a well-established infrastructure for clinical trials support market growth.

The region is also witnessing increased investments in neurological research, which fosters the development of new therapeutic modalities. While Europe and Asia-Pacific are emerging markets with growing demand, North America's established healthcare ecosystem continues to set the pace, making it a focal point for both existing players and new entrants looking to innovate in intracranial therapeutic delivery.

Intracranial Therapeutic Delivery Market- Competitive Landscape:

The intracranial therapeutic delivery market is characterized by intense competition among established players and emerging biotech firms. Key companies like Medtronic and AbbVie dominate with their extensive product portfolios and robust R&D capabilities, focusing on advanced drug delivery systems and innovative therapies for neurological conditions. Additionally, Stryker and Boston Scientific leverage their strong presence in surgical devices to enhance therapeutic outcomes.

Emerging players, such as NeuroRx and Zynerba Pharmaceuticals, are introducing novel treatment modalities, including cannabinoid-based therapies, which diversify the market landscape. Collaboration and strategic partnerships are common as companies seek to accelerate innovation and expand their market reach. Regulatory challenges and the need for clinical validation remain critical hurdles, influencing competitive strategies. Overall, the market is poised for growth as advancements in technology and a deeper understanding of neurological diseases drive new product development.

Recent Developments:

In September 2024, CereVasc's endovascular device has the potential to serve as a novel delivery system for gene therapy directly to the brain, improving treatment efficacy for neurological conditions. By utilizing this approach, aims to enhance targeted therapy while minimizing invasiveness and side effects associated with traditional methods.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic
  • AbbVie
  • Stryker Corporation
  • Baxter International
  • Ipsen S.A.
  • Johnson & Johnson (Ethicon)
  • NuVasive
  • NeuroRx
  • CureVac AG
  • Boston Scientific
  • Aesculap
  • Zynerba Pharmaceuticals
  • Elekta
  • Intra-Cellular Therapies

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis
  • Others

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Intracranial Therapeutic Delivery Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Intracranial Therapeutic Delivery Market Snippet by Therapy
    • 2.1.2. Intracranial Therapeutic Delivery Market Snippet by Indication
    • 2.1.3. Intracranial Therapeutic Delivery Market Snippet by Country
    • 2.1.4. Intracranial Therapeutic Delivery Market Snippet by Region
  • 2.2. Competitive Insights

3. Intracranial Therapeutic Delivery Key Market Trends

  • 3.1. Intracranial Therapeutic Delivery Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Intracranial Therapeutic Delivery Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Intracranial Therapeutic Delivery Market Opportunities
  • 3.4. Intracranial Therapeutic Delivery Market Future Trends

4. Intracranial Therapeutic Delivery Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Intracranial Therapeutic Delivery Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Intracranial Therapeutic Delivery Market Landscape

  • 6.1. Intracranial Therapeutic Delivery Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Intracranial Therapeutic Delivery Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
    • 7.1.2. Cell-based Therapy
    • 7.1.3. Gene Therapy
    • 7.1.4. Enzyme Replacement Therapy

8. Intracranial Therapeutic Delivery Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Spinal Muscular Atrophy (SMA)
    • 8.1.3. Multiple Sclerosis
    • 8.1.4. Batten Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis
    • 8.1.6. Others

9. Intracranial Therapeutic Delivery Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Intracranial Therapeutic Delivery Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Intracranial Therapeutic Delivery Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Intracranial Therapeutic Delivery Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Intracranial Therapeutic Delivery Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Intracranial Therapeutic Delivery Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Intracranial Therapeutic Delivery Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Medtronic
    • 10.2.2. AbbVie
    • 10.2.3. Stryker Corporation
    • 10.2.4. Baxter International
    • 10.2.5. Ipsen S.A.
    • 10.2.6. Johnson & Johnson (Ethicon)
    • 10.2.7. NuVasive
    • 10.2.8. NeuroRx
    • 10.2.9. CureVac AG
    • 10.2.10. Boston Scientific
    • 10.2.11. Aesculap
    • 10.2.12. Zynerba Pharmaceuticals
    • 10.2.13. Elekta
    • 10.2.14. Intra-Cellular Therapies

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us